JP2019506862A5 - - Google Patents

Download PDF

Info

Publication number
JP2019506862A5
JP2019506862A5 JP2018540030A JP2018540030A JP2019506862A5 JP 2019506862 A5 JP2019506862 A5 JP 2019506862A5 JP 2018540030 A JP2018540030 A JP 2018540030A JP 2018540030 A JP2018540030 A JP 2018540030A JP 2019506862 A5 JP2019506862 A5 JP 2019506862A5
Authority
JP
Japan
Prior art keywords
rna complex
rna
antisense strand
cells
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540030A
Other languages
English (en)
Japanese (ja)
Other versions
JP7003044B2 (ja
JP2019506862A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000167 external-priority patent/WO2017134526A1/en
Publication of JP2019506862A publication Critical patent/JP2019506862A/ja
Publication of JP2019506862A5 publication Critical patent/JP2019506862A5/ja
Application granted granted Critical
Publication of JP7003044B2 publication Critical patent/JP7003044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540030A 2016-02-02 2017-02-01 Ａｎｇｐｔ２およびｐｄｇｆｂを標的化するｒｎａ複合体を用いる血管新生関連疾患の処置 Active JP7003044B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290330P 2016-02-02 2016-02-02
US62/290,330 2016-02-02
PCT/IB2017/000167 WO2017134526A1 (en) 2016-02-02 2017-02-01 Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb

Publications (3)

Publication Number Publication Date
JP2019506862A JP2019506862A (ja) 2019-03-14
JP2019506862A5 true JP2019506862A5 (enExample) 2020-03-12
JP7003044B2 JP7003044B2 (ja) 2022-01-20

Family

ID=59386437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540030A Active JP7003044B2 (ja) 2016-02-02 2017-02-01 Ａｎｇｐｔ２およびｐｄｇｆｂを標的化するｒｎａ複合体を用いる血管新生関連疾患の処置

Country Status (7)

Country Link
US (2) US10519449B2 (enExample)
EP (1) EP3411481A4 (enExample)
JP (1) JP7003044B2 (enExample)
KR (1) KR102825945B1 (enExample)
CN (1) CN108779464B (enExample)
CA (1) CA3022877A1 (enExample)
WO (1) WO2017134526A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3599280B1 (en) 2010-10-22 2022-11-02 OliX Pharmaceuticals, Inc. Nucleic acid molecules inducing rna interference, and uses thereof
CN104755620B (zh) 2012-05-22 2018-03-02 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及其用途
KR102727666B1 (ko) 2015-11-16 2024-11-08 올릭스 주식회사 MyD88 또는 TLR3을 타겟팅하는 RNA 복합체를 이용한 연령-관련 황반 변성의 치료
KR102825946B1 (ko) 2016-02-02 2025-06-27 올릭스 주식회사 IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
US10519449B2 (en) 2016-02-02 2019-12-31 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
KR102339886B1 (ko) 2016-04-11 2021-12-17 올릭스 주식회사 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (en) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE
KR102397455B1 (ko) * 2019-05-20 2022-05-13 올릭스 주식회사 PD-1의 발현을 억제하는 비대칭 siRNA
WO2025067351A2 (en) * 2023-09-27 2025-04-03 Neuro3 Therapeutics, Inc. Novel sirna constructs, therapeutics, and modifications

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20080188430A1 (en) 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
JP2005506087A (ja) 2001-10-26 2005-03-03 リボファーマ アーゲー プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用
US20040138163A1 (en) 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
PT1527176E (pt) 2002-08-05 2007-04-30 Atugen Ag Novas formas de muléculas de arn de interferência
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2216407B1 (en) 2003-03-07 2016-01-13 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005079533A2 (en) 2004-02-17 2005-09-01 University Of Massachusetts Methods and compositions for mediating gene silencing
EP2365077B1 (en) 2004-03-12 2013-05-08 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
JP2008512500A (ja) 2004-09-10 2008-04-24 ソマジェニックス インコーポレーティッド ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法
NZ586217A (en) 2004-09-24 2011-12-22 Alnylam Pharmaceuticals Inc RNAI modulation of APOB and uses thereof
US20060142228A1 (en) 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
WO2006110688A2 (en) 2005-04-08 2006-10-19 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
WO2006125977A2 (en) 2005-05-25 2006-11-30 The University Of York Hybrid interfering rna
NZ564375A (en) 2005-06-24 2010-02-26 Intervet Int Bv Inactivated chimeric flavivirus vaccines and related methods of use
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
WO2007092182A2 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
US20070218495A1 (en) 2006-03-16 2007-09-20 Dharmacon, Inc. Methods, libraries and computer program products for gene silencing with reduced off-target effects
US7700541B2 (en) 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008109372A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pdgf gene expression and uses thereof
WO2008109377A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
CA2691617C (en) 2007-05-31 2020-07-21 University Of Iowa Research Foundation Reduction of off-target rna interference toxicity
US20090004668A1 (en) 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
CN101959521A (zh) * 2007-07-06 2011-01-26 因特拉迪格姆公司 用于治疗癌症和其他血管生成相关疾病的方法和组合物
WO2009020344A2 (en) 2007-08-06 2009-02-12 Postech Acad Ind Found Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
WO2009029688A2 (en) 2007-08-27 2009-03-05 Boston Biomedical, Inc. Compositions of asymmetric interfering rna and uses thereof
DK2195428T3 (en) 2007-09-19 2014-03-03 Applied Biosystems Llc SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF
US8614309B2 (en) 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
KR100949791B1 (ko) * 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
JP2011518116A (ja) 2008-02-21 2011-06-23 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション トール様受容体３拮抗薬としての超小型ｒｎａ
CA2731779A1 (en) 2008-07-24 2010-01-28 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
JP5294344B2 (ja) 2008-09-08 2013-09-18 学校法人福岡大学 白血病治療用医薬組成物
CN102405286A (zh) 2008-09-22 2012-04-04 阿克赛医药公司 减小大小的自递送RNAi化合物
US20100227920A1 (en) 2008-09-29 2010-09-09 The Regents Of The University Of California Aldehyde dehydrogenase inhibitors as novel depigmenting agents
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2398903A1 (en) * 2009-02-18 2011-12-28 Silence Therapeutics Aktiengesellschaft Means for inhibiting the expression of ang2
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN104651362A (zh) 2009-04-03 2015-05-27 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
US8472766B2 (en) 2009-08-14 2013-06-25 Massachusetts Institute Of Technology Waveguide coupler having continuous three-dimensional tapering
KR101207561B1 (ko) 2009-12-15 2012-12-04 주식회사 코리아나화장품 티로시나제의 발현을 저해하는 ｓｉＲＮＡ 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
CA2834108A1 (en) 2010-05-12 2011-11-17 Val-Chum, Limited Partnership Screening assays based on mag and/or abhd6 for selecting insulin secretion promoting agents
WO2012037254A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
CN103080314B (zh) * 2010-09-30 2016-04-13 Lsip基金运营联合公司 显性突变基因表达抑制剂
EP3599280B1 (en) 2010-10-22 2022-11-02 OliX Pharmaceuticals, Inc. Nucleic acid molecules inducing rna interference, and uses thereof
EP2649181B1 (en) 2010-12-06 2016-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
CN102719432B (zh) 2011-03-29 2013-10-23 南京大学 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
KR101590586B1 (ko) 2011-05-30 2016-02-01 성균관대학교산학협력단 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ
CN104755620B (zh) 2012-05-22 2018-03-02 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及其用途
US9611473B2 (en) 2012-09-12 2017-04-04 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
US20160122764A1 (en) 2013-07-05 2016-05-05 Bioneer Corporation Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease
EP3027223A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US9790506B2 (en) 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US20170226507A1 (en) 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US9139648B1 (en) * 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3277811B1 (en) 2015-04-03 2020-12-23 University of Massachusetts Fully stabilized asymmetric sirna
WO2017017523A1 (en) 2015-07-27 2017-02-02 Olix Pharmaceuticals, Inc. Rna complexes that inhibit melanin production
KR102727666B1 (ko) 2015-11-16 2024-11-08 올릭스 주식회사 MyD88 또는 TLR3을 타겟팅하는 RNA 복합체를 이용한 연령-관련 황반 변성의 치료
US10519449B2 (en) 2016-02-02 2019-12-31 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
KR102825946B1 (ko) 2016-02-02 2025-06-27 올릭스 주식회사 IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
KR102339886B1 (ko) 2016-04-11 2021-12-17 올릭스 주식회사 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (en) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE

Similar Documents

Publication Publication Date Title
JP2019506862A5 (enExample)
JP7420866B2 (ja) 核酸ポリペプチド組成物とその使用
JP2024001021A (ja) 核酸ポリペプチド組成物およびその使用
Zhou et al. Aptamers: A promising chemical antibody for cancer therapy
Sun et al. Oligonucleotide aptamers: new tools for targeted cancer therapy
AU2013306006B2 (en) Polynucleotides having bioreversible groups
CN110753756B (zh) 免疫调节性多核苷酸及其应用
JP2016535009A5 (enExample)
JP2016520312A5 (enExample)
Jiang et al. Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy
JP7038045B2 (ja) ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法
JP2008056679A5 (enExample)
JP2018536689A5 (enExample)
WO2012094653A4 (en) Compositions and methods for macromolecular drug delivery
JP2017523985A5 (enExample)
JP2018533956A5 (enExample)
JP6847852B2 (ja) 癌治療のためのヒト抗原Ｒ発現のｓｉＲＮＡ阻害
JP2018534361A5 (enExample)
US20160304874A1 (en) High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
JP2017514800A5 (enExample)
CN110573166B (zh) 用于癌症治疗的吉西他滨衍生物
AU2018314236A1 (en) RNA aptamers against transferrin receptor (TfR)
JP6536964B2 (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
JP2019529571A5 (enExample)
JP2013504603A5 (enExample)